NCCN Expands Hereditary Cancer Genetic Testing Access: What Changed in September 2026
Short answer: On September 14, 2026, NCCN updated its Genetic/Familial High-Risk Assessment guidelines to drop age and family-history gatekeeping for colorectal, endometrial, and gastric cancer patients — every diagnosed patient now qualifies for multigene panel testing. The update also adds new esophageal cancer testing sections and expands neuroendocrine/adrenal tumor risk assessment. Because payers and Medicare Administrative Contractors lean on NCCN as the clinical authority behind medical-necessity criteria, this quietly widens who labs, genetic counselors, and ordering clinicians can test — and who payers are expected to cover.
What NCCN actually changed
The National Comprehensive Cancer Network's Genetic/Familial High-Risk Assessment guideline family covers the criteria clinicians use to decide who qualifies for hereditary cancer risk evaluation and multigene panel testing. The September 2026 update touches several of these guidelines at once, and the direction is consistent across all of them: broaden eligibility, remove restrictive gates, and test earlier.
Colorectal, endometrial, and gastric cancer: age and family history no longer required
The most consequential change is in the Colorectal, Endometrial, and Gastric guideline. Multigene panel testing is now recommended for all diagnosed patients, regardless of age or family history — a shift away from the longstanding practice of reserving testing for younger patients or those with a documented family pattern of cancer. Multigene panel testing is now positioned as the preferred, earlier approach to hereditary cancer risk evaluation rather than a second-line option triggered by red flags.
Esophageal cancer: a new dedicated pathway
NCCN added dedicated sections for esophageal cancer covering screening, risk evaluation, and genetic testing — a guideline area that previously had no standalone hereditary risk-assessment pathway.
Neuroendocrine and adrenal tumors: a new section, tested at any age
A new hereditary cancer risk-assessment section for neuroendocrine and adrenal tumors was created, with expanded testing recommendations that include thymic neuroendocrine tumors at any age.
Breast, ovarian, pancreatic, and prostate cancer: Version 2.2026
NCCN also published Version 2.2026 of its Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate guideline, the periodic update cycle that keeps testing criteria current with new evidence for the cancer types genetic-testing labs handle most often.
Why an NCCN guideline update moves reimbursement, not just clinical practice
NCCN guidelines are not just a clinical reference — they are written directly into Medicare coverage policy. CMS's own Local Coverage Determination for BRCA1 and BRCA2 genetic testing (L36499) cites NCCN guidelines repeatedly as the standard for comprehensive testing scope, pretest and posttest counseling, and the criteria multigene panels must meet, stating that panel testing is covered when a patient meets criteria "for which NCCN guidelines provide clear testing criteria and management recommendations." MolDX local coverage policy for hereditary cancer testing is built the same way across contractors. That means a change to NCCN's eligibility criteria doesn't stay confined to clinical guidance — it becomes the reference point payers, Medicare Administrative Contractors, and internal medical policy teams use to define who "meets criteria" for a covered test. When NCCN widens the population that qualifies for colorectal, endometrial, and gastric multigene panels, it widens the population labs can point to as meeting medical necessity, even before any single LCD is formally rewritten to match.
What this means for ordering clinicians and genetic counselors
The practical effect for ordering clinicians is fewer edge cases where a clearly indicated patient gets turned away at the intake stage for lacking a documented family history or falling outside an age cutoff. For genetic counselors fielding referrals from oncology and gastroenterology, this removes a common source of friction: patients diagnosed with colorectal, endometrial, or gastric cancer no longer need to clear an age or pedigree bar before a multigene panel conversation can happen. Expect referral volume from these cancer types to rise as ordering physicians become aware of the change and update their own intake criteria accordingly.
What this means for labs and revenue cycle teams
For molecular labs and RCM teams — including hereditary-cancer testing labs like ScreenMyGene — three operational items follow directly from this update:
1. Update test requisition and eligibility logic. Any internal criteria, order forms, or EHR decision-support rules that still gate colorectal, endometrial, or gastric multigene panel orders behind age or family-history fields should be revised to reflect the broadened NCCN criteria, so appropriate orders aren't rejected at intake.
2. Expect volume growth without an automatic coverage rewrite. A published NCCN update does not instantly rewrite every payer's medical policy or LCD language. Some payers will update medical necessity criteria promptly; others will lag. Labs should be ready to cite the updated NCCN guideline directly in prior authorization and appeal documentation while payer policies catch up — the same pattern seen after past NCCN expansions.
3. Watch downstream coding and coverage infrastructure. Broader testing eligibility interacts with the reimbursement machinery covered elsewhere on this site — CPT and PLA code assignment, MolDX registration, and the possibility of MolDX's registration model expanding nationally. A jump in colorectal, endometrial, and gastric panel volume is exactly the kind of utilization shift that shows up in future CLFS rate-setting data and MAC coverage reviews.
Who is behind the push, and why it matters for the industry
The update was welcomed by the INTERACT coalition — laboratory and diagnostics companies including Ambry Genetics, Illumina, Myriad Genetics, Natera, Quest Diagnostics, and My Gene Counsel — alongside patient advocacy organizations such as FORCE, AliveandKick'n, and the Ovarian Cancer Research Alliance. AliveandKick'n executive director Robin Dubin framed the rationale simply: earlier, broader genetic testing means earlier surveillance and prevention. That alignment between industry and patient advocacy groups is notable — it signals sustained pressure to keep widening testing eligibility rather than a one-time guideline adjustment, and it is worth watching for follow-on advocacy toward payers that are slow to update medical policy.
What to watch next
Three things are worth tracking as this update moves from guideline to daily practice: whether major MACs and commercial payers formally revise their multigene panel LCDs and medical policies to mirror the new NCCN language; whether colorectal, endometrial, and gastric panel order volume rises in a way that shows up in future CLFS rate-setting data; and whether this becomes a factor in the broader debate over MolDX's potential national registration expansion, since a larger eligible testing population strengthens the case payers have made for tighter pre-registration controls.
Frequently asked questions
What exactly did NCCN change in its September 2026 hereditary cancer guidelines?
NCCN removed age and family-history requirements for multigene panel testing in diagnosed colorectal, endometrial, and gastric cancer patients, added new esophageal cancer testing sections, expanded neuroendocrine/adrenal tumor risk assessment, and released Version 2.2026 of its breast/ovarian/pancreatic/prostate guideline.
Does this mean Medicare and commercial payers will automatically cover more genetic tests?
Not automatically. NCCN guidelines heavily inform LCDs and payer medical policy, as seen in CMS's BRCA1/BRCA2 LCD (L36499), but each payer updates its own policy on its own timeline. Labs should expect to cite the new NCCN criteria directly during prior authorization and appeals while payer policies catch up.
Which cancer types are affected by the update?
Colorectal, endometrial, and gastric cancers see the most significant change (testing regardless of age or family history). Esophageal cancer gets a new dedicated testing pathway, neuroendocrine and adrenal tumors get a new risk-assessment section, and breast/ovarian/pancreatic/prostate guidelines were refreshed to Version 2.2026.
Do labs need to change their test order or requisition criteria right away?
Labs and health systems with internal eligibility logic tied to the old age or family-history gates should update requisition forms and EHR decision support to reflect the broadened NCCN criteria, so appropriately indicated patients aren't turned away at intake.
Where can clinicians and lab staff find the updated guidelines?
The current NCCN Genetic/Familial High-Risk Assessment guidelines are published at NCCN.org under Guidelines for Detection, Prevention, and Risk Reduction; free registration is required to view full guideline detail, consistent with NCCN's standard access policy.
This article summarizes a clinical guideline update and its general reimbursement context as of September 2026, for general information only. It is not billing, legal, coding, or medical advice. Coverage and medical necessity determinations vary by payer and Medicare Administrative Contractor; verify current criteria against the applicable NCCN guideline, LCD, and payer medical policy before submitting orders or claims.
Sources: NCCN, "Cancer Genetic Risk Assessment Guidelines Expand Access to Testing" (nccn.org, September 14, 2026); PR Newswire, "INTERACT Supports Updated NCCN Guidelines that Expand Access to Appropriate Hereditary Cancer Genetic Testing"; CMS Medicare Coverage Database, LCD L36499 (BRCA1 and BRCA2 Genetic Testing); NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026 (PubMed). See also ScreenMyGene's Medicare coverage guide for genetic testing, guide to why genetic testing claims get denied, and coverage of MolDX's proposed national expansion.